Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · IEX Real-Time Price · USD
15.50
+0.54 (3.61%)
May 17, 2024, 4:30 PM EDT - Market closed
Contineum Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for CTNM stock have an average target of 28, with a low estimate of 25 and a high estimate of 30. The average target predicts an increase of 80.65% from the current stock price of 15.50.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CTNM stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '24 |
|---|---|
| Strong Buy | 1 |
| Buy | 2 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Initiates $29 | Strong Buy | Initiates | $29 | +87.10% | Apr 30, 2024 |
| RBC Capital | RBC Capital | Buy Initiates $30 | Buy | Initiates | $30 | +93.55% | Apr 30, 2024 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $25 | Buy | Initiates | $25 | +61.29% | Apr 30, 2024 |
Financial Forecast
Revenue This Year
n/a
from 50.00M
Revenue Next Year
n/a
EPS This Year
n/a
from 0.08
EPS Next Year
n/a
Revenue Forecast
No data available
Revenue Growth
No data available
EPS Forecast
No data available
EPS Growth
No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.